Skip to main content

Company

Gilead Sciences

87 published works

  1. Product Perspective: Complex Tort & Product Law

    Gilead Tenofovir Cases: California Supreme Court Rejects Duty to Innovate or Accelerate Development of Alternatives to Non-Defective Products

    By Hilda Akopyan, Malea Casillas, Magda Patitsas

    Can a pharmaceutical manufacturer face liability for failing to bring an allegedly safer drug to market sooner, even when the drug it already sells is not defective? In Gilead Tenofovir…

  2. Regulatory Oversight

    Texas Reaches $45M Settlement With Gilead to Resolve Medicaid Kickback Allegations Over Patient-Support Programs

    By Troutman Pepper Locke State Attorneys General Team

    The state of Texas secured a $45 million settlement from Gilead Sciences Inc. over allegations that its patient-support programs improperly encouraged prescriptions for drugs covered by Medicaid. This case highlights…

  3. Drug & Device Law

    California’s Recent Gilead Decision Explains Why “Pre-Approval” Tort Claims Don’t, and Shouldn’t, Exist

    By Bexis

    Nearly a decade ago we published the blogpost “Pre-Approval Design Defects – No Such Thing.”  As we discussed, “pre-approval” design (later joined by warning) claims were a transparent preemption dodge. …

  4. Spicy IP

    Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics

    By Ambika Aggarwal

    July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from India by…

  5. Faeger Drinker on Products

    California Supreme Court Rejects Duty to Innovate

    By Josh Anderson

    On August 3, 2026, the California Supreme Court issued its decision in the closely watched Gilead Tenofovir Cases, No. S283862, — Cal.5th —, 2026 WL 2223748 (Cal. Aug. 3, 2026),…

  6. Drug & Device Law

    No Duty to Innovate: California Supreme Court Rejects New Negligence Theory

    By Steven Boranian

    The California Supreme Court handed down its long-awaited decision in Gilead Tenofovir Cases yesterday, and as we hoped, the Court held that a drug manufacturer owes no duty of care…

  7. The Virginia Defamation Law Blog

    Virginia’s Vicarious-Liability Presumption Applies at Pleading Stage

    By Lee E. Berlik

    Several years ago, this blog covered Garnett v. Remedi SeniorCare of Virginia, LLC, 892 F.3d 140 (4th Cir. 2018), in which the Fourth Circuit held that an employer could not…

  8. In-House Ops

    Goodwin’s Life Sciences Deal Flow Points to a More Selective M&A Market

    By Corporate Counsel Business Journal

    Life sciences M&A is back, but not as a free-for-all.Goodwin positions itself around a clear 2026 market signal: Life sciences M&A has reemerged as a competitive arena after a quieter…

  9. Product Perspective: Complex Tort & Product Law

    Gilead Tenofovir “Alternative Product” Duty at the CA Supreme Court: What It Means for Manufacturers

    By Natalie Garcia Lashinsky, Ronald Tran, James Battle

    A California Court of Appeal decision recognizing an unusual and potentially far-reaching negligence duty for product manufacturers is now before the California Supreme Court. In the Gilead Tenofovir Cases, the Court…

  10. Drug & Device Law

    California Supreme Court Hears Argument On The “Duty to Innovate”

    By Steven Boranian

    We observed arguments last week in the California Supreme Court in Gilead Tenofovir Cases, and quality advocates on both sides put on a great performance.  As we previewed last week,…